Production (Stage)
Carisma Therapeutics, Inc.
CARM
$0.4376
$0.00791.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.77M | -60.48M | -63.80M | -72.50M | -81.22M |
| Total Depreciation and Amortization | 2.32M | 3.35M | 3.41M | 3.37M | 3.83M |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Non-Cash Items | 7.94M | 9.16M | 10.60M | 10.63M | 8.18M |
| Change in Net Operating Assets | -7.05M | -11.95M | -17.87M | -17.14M | -8.86M |
| Cash from Operations | -47.56M | -59.92M | -67.66M | -75.64M | -78.07M |
| Capital Expenditure | -106.00K | -123.00K | -684.00K | -873.00K | -1.01M |
| Sale of Property, Plant, and Equipment | 524.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 11.00M | 41.00M | 77.00M |
| Cash from Investing | 418.00K | -123.00K | 10.32M | 40.13M | 75.99M |
| Total Debt Issued | 0.00 | 686.00K | 686.00K | 849.00K | 777.00K |
| Total Debt Repaid | -1.75M | -2.74M | -2.73M | -3.62M | -3.84M |
| Issuance of Common Stock | 136.00K | 2.42M | 3.11M | 3.02M | 3.07M |
| Repurchase of Common Stock | -23.00K | -23.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -758.00K | -4.22M |
| Cash from Financing | -1.63M | 344.00K | 1.07M | -507.00K | -4.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.78M | -59.70M | -56.28M | -36.02M | -6.29M |